Novartis/QLT Visudyne Expanded Indications Cover Up To 250,000 Patients

The approval of Novartis/QLT's Visudyne (verteporfin) for use in pathologic myopia and presumed ocular histoplasmosis could double the labeled patient population for the ophthalmic agent.